Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults by Fehintola, Fatai A. et al.
Hindawi Publishing Corporation
AIDS Research and Treatment
Volume 2012, Article ID 703604, 6 pages
doi:10.1155/2012/703604
Research Article
Nevirapine-BasedAntiretroviralTherapyImpactsArtesunateand
DihydroartemisininDisposition in HIV-Infected NigerianAdults
FataiA.Fehintola,1 Kimberly K. Scarsi,2 QingMa,3 Sunil Parikh,4
GeneD.Morse,3 Babafemi Taiwo,2 Ibrahim Tope Akinola,5 IsaacF. Adewole,6
Niklas Lindegardh,7 Aphiradee Phakderaj,7 Oladosu Ojengbede,6
Robert L.Murphy,2 OlusegunO.Akinyinka,8 andFrancesca T. Aweeka9
1Department of Clinical Pharmacology, University College Hospital and Department of Pharmacology & Therapeutics,
College of Medicine, University of Ibadan, Ibadan, Nigeria
2Division of Infectious Diseases & Center for Global Health,
Northwestern University Feinberg School of Medicine, Chicago, IL 60614, USA
3Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Department of
Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buﬀalo, Buﬀalo, NY 14203, USA
4Department of Medicine, San Francisco General Hospital, University of California, San Francisco,
San Francisco, California, CA 94110, USA
5Department of Obstetrics & Gynecology, University College Hospital, Ibadan, Nigeria
6Department of Obstetrics & Gynecology, College of Medicine, University of Ibadan, Ibadan, Nigeria
7Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
8Department of Pediatrics, College of Medicine, University of Ibadan, Ibadan, Nigeria
9Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco,
San Francisco, CA 94110, USA
Correspondence should be addressed to Olusegun O. Akinyinka, asegun@hotmail.com
Received 16 October 2011; Accepted 15 December 2011
Academic Editor: Gary Maartens
Copyright © 2012 Fatai A. Fehintola et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Nevirapine- (NVP-) based antiretroviral therapy (ART) and artesunate-amodiaquine are frequently coprescribed
in areas of HIV and malaria endemicity. We explored the impact of this practice on artesunate and dihydroartemisinin
pharmacokinetics.Methods.Weconductedaparallel-grouppharmacokineticcomparisonbetweenHIV-infectedpatientsreceiving
NVP-based ART (n = 10) and ART-naive controls (n = 11). Artesunate-amodiaquine 200/600mg was given daily for three
days. Measurement of drug concentrations occurred between 0 and 96 hours after the ﬁnal dose. Pharmacokinetic parameters
were determined using noncompartmental analysis. Results. Comparing the NVP group to controls, clearance of artesunate was
reduced 50% (1950 versus 2995 L/h; P = 0.03), resulting in a 45% increase in the AUC0−96 (105 versus 69ug∗hr/L; P = 0.02).
The half-life of dihydroartemisinin was shorter in the NVP group (1.6 versuss 3.2h; P = 0.004), but other dihydroartemisinin
pharmacokinetic parameters were unchanged. A lower conversion of artesunate to dihydroartemisinin was observed in the
NVP group (dihydroartemisinin: artesunate AUC0−96 = 5.6v e r s u s s8 . 5i nN V Pa n dc o n t r o lg r o u p s ,r e s p e c t i v e l y ,P = 0.008).
Conclusion. Although NVP-containing ART impacted some pharmacokinetic parameters of artesunate and dihydroartemisinin,
overall exposure was similar or better in the NVP group.
1.Introduction
Malaria remains a disease of public health importance with
an estimated 169–294 million cases in 2009, resulting in
approximately 781,000 deaths [1]. Sub-Saharan Africa not
only carries a high burden of the morbidity and mortality
associated with malaria but also a disproportionate burden
of HIV disease. An estimated 33.3 million people are living2 AIDS Research and Treatment
with HIV throughout the world, with more than 65%
living in sub-Saharan Africa, contributing 72% of the global
HIV/AIDS-related mortality in 2009 [2]. HIV and malaria
comorbidity is common given the overlapping geographic
areas aﬀected by both diseases [3, 4]. The safe and eﬀective
treatment of these common coinfections is a public health
priority.
As part of eﬀorts to combat drug resistance, the World
Health Organization (WHO) ﬁrst recommended the use of
artemisinin-based combination therapy (ACT) for malaria
in 2006 [5] and upheld this recommendation in the 2010
guidelines [6]. Based on this recommendation, artesunate-
amodiaquine is one of two regimens endorsed in the Nigeria
Malaria Treatment Policy since 2005 while the other is
artemether-lumefantrine [7]. Both regimens are used at
all levels of care in Nigeria, from home management to
tertiary care facilities. Artemisinin resistance has emerged
since the initial 2006 WHO malaria treatment guidelines
[5, 6], emphasizing the need for vigilant use of these essential
medications.
Many HIV-infected patients receiving combination anti-
retroviral therapy (ART) will inevitably require concomitant
use of an ACT in many regions of the world. The complex
pharmacology of both ACTs and antiretroviral drugs lends
concern to the safe and eﬀective use of these agents in com-
bination. Artesunate is primarily metabolized via esterase-
mediated hydrolysis, but also by the cytochrome p450 (CYP)
2A6 isoenzyme, to the active metabolite dihydroartemisinin
(DHA) [8]. DHA is subsequently metabolized via uridine
diphosphate glucuronosyltransferases (UGTs) 1A9 and 2B7,
and excreted in the bile [9]. Generally, both artesunate
and DHA are moderately to highly protein bound with an
elimination half-life of less than one hour, although DHA
has a marginally longer half-life than artesunate [10–12].
Artesunate and DHA both possess antimalarial activity, with
DHA being the more potent of the two. Therefore, any drug
interaction assessment of artesunate must consider both
artesunate and DHA.
Nevirapine (NVP), a nonnucleoside reverse transcriptase
inhibitor (NNRTI), is a component of most ﬁrst-line ART
regimensinsub-SaharanAfrica.NVPismetabolizedviaCYP
3A4andCYP2B6andinducesitsownmetabolismviainduc-
tion of CYP 3A4 and perhaps 2B6 [13–15]. The potential
for pharmacokinetic interactions between ACT and NVP
has not been fully explored. Unfavourable pharmacokinetic
drug interactions may lead to supratherapeutic antimalarial
or antiretroviral concentrations, resulting in toxicity or, con-
versely, subtherapeutic concentrations resulting in treatment
failure or drug resistance. There is also the potential for
positivepharmacologicinteractions,whichmaybebeneﬁcial
to patients with malaria and HIV co-infection. In either
instance, there is an urgent need to investigate the potential
drug interactions resulting from the coadministration of
NVP and ACT. Therefore, the primary objective of this study
was to explore the pharmacokinetic interactions between
NVPandartesunatetakenincombinationwithamodiaquine
in asymptomatic HIV-infected Nigerian adults by evaluating
the disposition kinetics of artesunate and DHA in the
presence and absence of steady-state NVP.
2.MaterialsandMethods
Patient recruitment, care, and follow up took place at the
University College Hospital, Ibadan, Nigeria. The University
of Ibadan/University College Hospital Institutional Review
Board approved this study, and all patients provided written,
informed consent. Eligible subjects had conﬁrmed HIV-
1 infection, were over 18 years of age, and had adequ-
ate renal and hepatic function, deﬁned as serum creati-
nine <1.5mg/dL and alanine transaminase and aspartate
transaminase <1.5 times the upper limit of normal, respec-
tively. Subjects were recruited into two groups: (1) NVP
groupand(2)controlgroup.SubjectsintheNVPgroupwere
on the same ART, consisting of lamivudine (3TC) 150mg,
zidovudine (AZT) 300mg, and NVP 200mg taken twice a
day for a minimum period of 8 weeks prior to study enrol-
ment, while all patients in the control group were not yet
receiving antiretroviral therapy. Pregnant women, patients
with known intolerance to study drugs, and patients who
used artemisinin derivatives or other drugs known to induce
or inhibit the CYP enzyme system in the preceding four
weekswereexcludedfromthestudy.Alltheparticipantswere
in a good state of health, with leukocyte, haemoglobin, and
hematocrit values within normal limits, no gastrointestinal
symptoms or other physical complaints as judged by their
primary physician. Patients remained on their current ART
(NVP group) or were ART-free (control group) for the
duration of the study.
A comprehensive history was obtained from individuals
who met the inclusion criteria, including duration of HIV
infection, drug history, and past medical history. Targeted
physical examination included pulse, blood pressure, weight
and height measurements. A capillary blood sample was
collected via ﬁnger prick for malaria screening; however the
results of the screening did not preclude study participation
a n do n ep a t i e n ti ne a c hs t u d yg r o u pw a sf o u n dt ob ep o s i t i v e
for malaria. In addition, about 10mls of venous blood was
drawn to determine baseline renal and hepatic function
as well as pretreatment artesunate pharmacokinetics. These
pretreatment samples were used to conﬁrm no patients
had detectable artesunate concentrations at the time of
initiating the study, but were not used in the pharmacoki-
netic analysis. Subsequently, each participant received oral
artesunate 200mg and amodiaquine 600mg daily for three
days. Samples for the determination of artesunate plasma
concentrations were collected according to the following
schedule: predose (0h) on the third day, and 0.5h, 1h, 1.5h,
2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, and 96h
after the 3rd and last dose of artesunate-amodiaquine. All
the samples were immediately centrifuged, separated, stored
in a −80◦C freezer, and were later batch shipped on dry ice
to the Clinical Pharmacology Laboratory at the Mahidol-
Oxford Tropical Medicine Research Unit in Thailand for
artesunate and DHA quantiﬁcation. A repeat sample to
assess renal and liver functions was taken on day 7 of the
study, or 96h following the last dose of the artesunate-
amodiaquine.AIDS Research and Treatment 3
2.1. Artesunate and Dihydroartemisinin Quantiﬁcation. The
plasma concentrations of artesunate and DHA were deter-
mined using solid-phase extraction and liquid chroma-
tography-tandem mass spectrometry on an API 5000 triple-
quadruple mass spectrometer (Applied Biosystems/MDS
SCIEX, Foster City, CA) with a TurboV ionization source
operated in the positive ion mode [16]. Stable isotope-
labeled artesunateand stableisotope-labeled DHA wereused
as internal standards. Total assay coeﬃcients of variation
during analysis of all batches for artesunate and DHA were
<6% at all quality control levels (5.87, 117, 1880ng/mL for
DHA, and 2.90, 51.7, 546ng/mL for artesunate). The lower
limits of quantiﬁcation (LLOQ) for artesunate and DHA
were set at 1.2 and 2.0ng/mL, respectively.
2.2. Pharmacokinetic and Statistical Analyses. Demographic
data were compared between the group on NVP and the
control group using epi-info version 6. Proportions were
compared using χ2 with Yates’ correction or Fisher’s exact
tests. Normally distributed, continuous data were compared
by Student’s t-test for independent groups. Standard non-
compartmental methods were used to estimate pharma-
cokinetic parameters. These parameters included the area
under the concentration-time curve (AUC0–96), maximum
plasma concentration (Cmax), time of Cmax (Tmax), elimina-
tion half-life (T1/2), apparent distribution volume (Vd/F),
and apparent oral clearance (CLss/F), where F is the oral
bioavailability. The maximum plasma concentration (Cmax)
and Tmax were estimated by inspection of the raw data.
Continuous variables were presented as the mean (standard
deviation) for subjects who participated in the study in
each group, except that the discontinuous variable, Tmax,
was given as median (range). The Kruskal-Wallis test was
used to determine P values for all parameters except Tmax,
where the Wilcoxon test was used, and the ratio of DHA
to artesunate AUC0–96 where the Mann Whitney U test was
most appropriate.
3. Results
3.1. Demographic and Clinical Characteristics. A total of 21
adult Nigerians consented and completed the study per
protocol: 10 participants were included in the NVP group
(7 (70%) female), while the other 11 constituted the control
group (8 (73%) female). The NVP group was relatively
older than the control group (mean (SD): 39.7 (13.5) versus
35.8 (6.4) years, respectively, P = 0.008), but the mean
body mass index was similar between groups (23.2 (2.9)
versus 22.8 (4.6) kg/m2; P = 0.6 ) .T h eN V Pg r o u pr e c e i v e d
NVP containing ART for a mean duration of 1.65 years
with shortest duration of exposure being 6 months; thus
all participants in the NVP group were at steady-state NVP
exposure. The mean CD4 counts for the NVP and control
groups were 415 (229)cells/mm3 and 438 (219) cells/mm3,
respectively (P = 0.82). None of the participants smoked
or consumed heavy alcohol. Artesunate-amodiaquine was
well tolerated in all participants, with the only reported side
eﬀect being moderate-to-severe weakness: 2/10 (20%) in the
NVP group, 1/11 (9%) in the control group, P = 0.93.
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Figure 1: Mean plasma concentration versus time proﬁle of
artesunate (0–6 hours).
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Figure 2: Mean plasma concentration versus time proﬁle of
dihydroartemisinin (0–12 hours).
Four individuals in the control group discontinued the study
protocol due to weakness, vomiting, diarrhoea, dizziness,
and anorexia. No individual in the NVP group experienced
treatment-limiting adverse eﬀects.
3.2. Pharmacokinetic Parameters. Pharmacokinetic parame-
ters of artesunate and DHA are presented in Table 1 and
Figure 1.Forartesunate,theVd/FoftheNVPgroupwas75%
smaller than that of the control group, while the Cl/F was
reduced by 50% in the NVP group (P = 0.01 and P = 0.03,
respectively). These changes resulted in a trend toward a
lower T1/2 in the NVP group (P = 0.06), owing to the Vd/F
and Cl/F, while the slower Cl/F in the NPV-group resulted
in a 45% increase in the artesunate AUC0–96 (P = 0.02).
No statistically signiﬁcant diﬀerences were seen with other
artesunate parameters.
The DHA pharmacokinetic parameters are presented in
Table 1 and Figure 2. While the Vd/F of DHA in patients on
NVP was 55% lower than control patients (P = 0.04), the
Cl/F of DHA was not diﬀerent between groups (P = 0.53).
This resulted in an overall shorter T1/2 in the NVP group
(P = 0.004),butnosigniﬁcantchangeintheoverallexposure
to DHA (P = 0.19). The ratio of DHA to artesunate, based
onacomparisonofAUC0–96,wasmarkedlylowerintheNVP4 AIDS Research and Treatment
Table 1: Comparison of pharmacokinetic parameters of artesunate and dihydroartemisinin.
Artesunate Nevirapine Group, n = 10 Control Group, n = 11 P-value
Mean (SD) Mean (SD)
Cmax (μg/mL) 108 (42) 71 (57) 0.15
Tmax (h)∗ 1.0 (0.5–2.0)∗ 1.0 (0.5–1.5)∗ 0.67
Cl/F (L/h) 1950 (543) 2995 (1180) 0.03
Vd/F (L) 1162 (856) 4525 (3535) 0.01
T1/2 (h) 0.4 (0.3) 1.1 (0.9) 0.06
AUC0–96 (μg ∗L/h) 105 (31) 69 (26) 0.02
Dihydroartemisinin Mean (SD) Mean (SD)
Cmax (μg/ml) 298 (107) 507 (429) 0.15
Tmax (h)∗ 1.0 (0.5–3.0)∗ 1.5 (0.5–6.0)∗ 0.11
Cl/F (L/h) 1130 (425) 980 (616) 0.53
Vd/F (L) 2405 (1077) 4338 (2518) 0.04
T1/2 (h) 1.6 (0.8) 3.2 (1.4) 0.004
AUC0–96 (μg ∗L/h) 603 (218) 883 (607) 0.19
∗Presented as median (range).
groupcomparedtothecontrolgroup;(median(intraquartile
range)) 5.6 (4.4–6.6) versus 8.5 (7.2–18.5), P = 0.008.
4. Discussion
Toourknowledge,thisstudyrepresentstheﬁrstinvestigation
of the disposition kinetics of artesunate and DHA in HIV-
infected adults with and without NVP containing ART.
Overall, despite a shorter T1/2 for both artesunate and DHA,
we found an increase in overall exposure (AUC0–96)o fa r t e -
sunate in patients receiving NVP compared to those not on
ART (105 versus 69ug ∗ L/hr; respectively; P = 0.02) and no
diﬀerence in the overall exposure to DHA. While the clinical
relevance of these results remains unclear, it is noteworthy
that the half-life of DHA was signiﬁcantly shorter when
given with NVP, and the conversion of artesunate to DHA
was lower in the NVP group. It is possible that a negative
impact of NVP on the disposition kinetics of artesunate and
DHA may be detected in larger studies. This demands an
observant approach to malaria therapy in individuals on
NVP containing ART until further investigation into the
impact of this interaction can be performed.
Given the metabolic pathways of artesunate (hydrol-
ysis and CYP2A6) and DHA (UGT 1A9 and 2B7), the
observed impact on artesunate and DHA pharmacokinetics
is unexpected. Nevirapine is well known for decreasing
exposure to coadministered medications due to induction
of the CYP3A4 and 2B6 isoenzymes [13–15]. Interestingly,
one other ACT-nevirapine interaction study described an in
vivo pharmacokinetic interaction where NVP both increased
and decreased exposure to the coadministered ACT [17].
KredoandcolleaguesdescribedtheinteractionbetweenNVP
and artemether-lumefantrine in HIV-infected subjects in
South Africa in which lumefantrine Day 7 concentrations
and AUC0–inf were increased in patients on NVP compared
to HIV-infected controls [17]. These directional changes
seen with the lumefantrine parameters when combined
with NVP are similar to our artesunate results, despite
diﬀerent metabolic pathways of the two antimalarial agents.
Contrary to our artemisinin pharmacokinetic results, Kredo
and colleagues found that the artemether and DHA AUC0–inf
were lower in the NVP group compared to controls [17].
Notably, diﬀerent CYP enzyme pathways metabolize arte-
sunate (CYP2A6) and artemether (CYP3A4), which may
account for the diﬀerence in artemisinin pharmacokinetic
ﬁndings observed in our study of artesunate compared to
the results of artemether plus NVP. Although the current
study was not designed to evaluate the mechanism of
this interaction, our observation of a lower conversion of
artesunate to DHA in the NVP group (DHA: artesunate
AUC0–96 = 5.6 versus 8.5 in NVP and control groups,
respectively, P = 0.008) is noteworthy. Further investigation
into the underlying mechanism of this unexpected change is
warranted.
The rateofmalariaparasite clearancehasbeenassociated
with the overall exposure to both parent drug and DHA
for other artemisinins [18]; hence reduction in the blood
concentrations of either or both components may negatively
impact on the antimalarial activity of the artemisinin
therapy. Reassuringly, our ﬁndings suggest that although the
T1/2 was shorter, the overall exposure of both artesunate
and DHA was similar compared to our control group and
indeed higher for artesunate. Artesunate is generally a well-
tolerated medication, particularly in comparison to other
nonartemisinin antimalarial medications [19]. Dizziness,
nausea, vomiting, and anorexia have been reported in
patients with malaria who were treated with artemisinin
monotherapy [19]. However, these toxicities were typically
transient and resolved after 1-2 days, raising some question
as to the relationship of the toxicity to the medication versus
the underlying infectious process. Given the relative safety of
artesunate,theobservedincreaseindrugexposurewouldnot
be expected to cause additional toxicity; however vigilance
for excess toxicity may be warranted.AIDS Research and Treatment 5
Artesunate and DHA are known to have wide interpa-
tient variability in their pharmacokinetic parameters, and
artesunate and DHA exposure are both decreased by the
co-administration of amodiaquine [20]. Additionally, the
pharmacology of these agents is known to be diﬀerent
between patients with acute malaria and healthy volunteers.
DHA total exposure was shown to be approximately 2-
fold higher in patients with active malaria than healthy
volunteers (4,024 versus 1,763nmol ∗ h/L) [21]. Addi-
tionally, the protein binding of DHA may change during
acute malaria infection related to plasma pH and circulating
α-1-acid glycoprotein [22]. Complicating the evaluation
of these important drug interactions further, diﬀerences
in antiretroviral pharmacokinetics and pharmacodynamics
exist between healthy volunteers and HIV infected patients
[22, 23]; therefore, it is conceivable that HIV-infection may
impact antimalarial drug concentrations as well.
There are some limitations in the present study that must
be considered. In addition to noncompartmental analysis of
artesunate and DHA, a comodelling approach that combines
the parent and metabolite is currently underway to more
fully describe the pharmacokinetic implications of chronic
NVPtherapyonartesunateandDHA.Thepharmacokinetics
of concurrent amodiaquine will be also described to fully
understand the impact of NVP on antimalarial treatment
with artesunate-amodiaquine. Although we have accommo-
dated for the potential impact of HIV infection on the
pharmacokinetics of artesunate and DHA by evaluating this
interaction in an HIV-infected population, the pharmacoki-
netic impact of this interaction may be diﬀerent in patients
with acute malarial infection.
5. Conclusions
In summary, in HIV-infected patients receiving NVP-con-
taining ART, standard multidose therapy with artesunate-
amodiaquine resulted in higher overall exposure to arte-
sunate and similar overall exposure to DHA, compared to
HIV-infected patients not yet receiving ART. However, the
conversion of artesunate to DHA was impaired in patients
receiving NVP, and the T1/2 of DHA was shorter, both
raising potential concern for the overall impact of NVP
on the eﬃcacy of artesunate. The impact of NVP on the
amodiaquine component of the antimalarial therapy will
provide additional insight into the safety and eﬃcacy of
combining artesunate-amodiaquine and NVP.
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